The 10-second takeaway
For the quarter ended June 30 (Q2), Antares Pharma missed estimates on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly and GAAP loss per share improved.
Margins dropped across the board.
Antares Pharma reported revenue of $4.5 million. The three analysts polled by S&P Capital IQ foresaw a top line of $4.6 million on the same basis. GAAP reported sales were 28% higher than the prior-year quarter's $3.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.03. The one earnings estimate compiled by S&P Capital IQ predicted -$0.03 per share. GAAP EPS were -$0.03 for Q2 compared to -$0.02 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 44.1%, 1,660 basis points worse than the prior-year quarter. Operating margin was -61.7%, 1,660 basis points worse than the prior-year quarter. Net margin was -62.0%, 1,810 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $6.4 million. On the bottom line, the average EPS estimate is -$0.01.
Next year's average estimate for revenue is $25.3 million. The average EPS estimate is -$0.04.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 161 members out of 176 rating the stock outperform, and 15 members rating it underperform. Among 21 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 16 give Antares Pharma a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Antares Pharma is buy, with an average price target of $4.50.
- Add Antares Pharma to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Antares Pharma Inc Plummeted Today
An FDA rejection is coming for the drugmaker's testosterone replacement therapy Xyosted.
Why Shares in Antares Pharma, Inc. Burst Today
Antares Pharma, Inc. shares tumbled after it priced its secondary stock offering.
3 Stocks Crushed by the Market This Week
Find out which health-care stocks got beaten down the most by the market over the past few days.